"Vast" reimbursement fraud exposed in France

15 October 2006

The French Health Ministry is expected to announce the formation of a national anti-fraud committee. According to local media reports, fairly basic scams have cost France's Social Security program 10.0-20.0 million euros ($12.7-$25.5 million) within the past year. Fraudsters are collecting a number of prescriptions for reimbursable drugs under the Social Security fund, before mailing the medications to foreign countries where they are sold for higher prices.

The illegal activity came to light following investigations by the sickness insurance national fund (CNAM), which formed an investigational unit in January this year. By cross-referencing the payments of local funds with a national database, the CNAM found a number of suspicious prescription patterns.

In one reported case, a patient consulted 40 physicians, obtaining in a six-month period 500 packs of cortisone-based ointments from 60 different pharmacies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight